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Abstract
A new simple, rapid and sensitive reversed-phase liquid chromatographic method was developed and validated for
the simultaneous determination of sulpiride (SUL) and mebeverine Hydrochloride (MEB) in the presence of their
impurities and degradation products. The separation of these compounds was achieved within 6 min on a 250
mm, 4.6 mm i.d., 5 m particle size Waters
®-C18 column using isocractic mobile phase containing a mixture of
acetonitrile and 0.01 M dihydrogenphosphate buffer (45:55) at pH = 4.0. The analysis was performed at a flow rate
of 1.0 mL/min with fluorescence-detection at excitation 300 nm and emission at 365 nm. The concentration-
response relationship was linear over a concentration range of 10- 100 ng/mL for both MEB and SUL with a limit
of detection 0.73 ng/mL and 0.85 ng/mL for MEB and SUL respectively. The proposed method was successfully
applied for the analysis of both MEB and SUL in bulk with average recoveries of 100.22 ± 0.757% and 99.96 ±
0.625% respectively, and in commercial tablets with average recoveries of 100.04 ± 0.93% and 100.03 ± 0.376% for
MEB and SUL respectively. The proposed method was successfully applied to the determination of MEB metabolite
(veratic acid) in real plasma simultaneously with SUL. The mean% recoveries (n = 3) for both MEB metabolite
(veratic acid) and SUL were 100.36 ± 2.92 and 99.06 ± 2.11 for spiked human plasma respectively. For real human
plasma, the mean% recoveries (n = 3) were and respectively.
Keywords: Sulpiride, mebeverine, mebeverine metabolite (veratic acid), HPLC fluorimetric detection, pharmaceuti-
cal preparations and human plasma
Introduction
Mebeverine hydrochloride (MEB) 3,4-Dimethoxybenzoic
acid 4- [ethyl[2-(4-methoxyphenyl)-1-methylethyl]
amino]-butylester (Figure 1) is a potent direct antispas-
modic acting mainly on the smooth muscles of the gas-
trointestinal tract and particularly effective against the
colonic spasm [1].
Mebeverine undergoes rapid and extensive presyste-
mic (first-pass) hydrolysis in the gut and/or the liver
into mebeverine alcohol and veratic acid [1].
British Pharmacopoeia described a non aqueous titri-
metric method for determination of MEB in pure form
[2].
Sulpiride (SUL) 5-(Aminosulfonyl)-N-[(1-ethyl-2-pyr-
rolidinyl)methyl]-2-methoxy-benzamide (Figure 1) is the
most widely prescribed anti-psychotic drug. It is a selec-
tive dopamine D2 antagonist with antidepressant activ-
ities it exerts a mood elevating effect and antiemetic
action [1].
Regarding SUL, British Pharmacopoeia described a
non aqeous titrimetric method for determination of SUL
in pure form [2].
Combination of MEB and SUL is used for treatment
gastrointestinal and colic spasms which are a conse-
quence of psychosomatic manifestation of nervous ten-
tion, mental stress or anxiety. MEB and SUL were
determined in their binary mixture via derivative spec-
troscopy [3,4], first derivative synchronous fluorescence
spectroscopy [5]. TLC- densitometry [4], HPLC [4-6]
and chemometric techniques [7].
T h ea i mo ft h ep r e s e n ts t udy is to establish and
develop a novel, sensitive and selective HPLC method
for simultaneous determination of MEB and SUL either
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human plasma as SUL and MEB metabolite (veratic
acid). However, to the best of our knowledge, no analy-
tical methods have been reported for the simultaneous
determination of all compounds in the presence of their
impurities and degradation products, which might inter-
fere with the analysis of the active ingredients
Experimental
Chromatographic conditions
- HPLC experiments were performed with a Merck
Hitachi L- 7100 chromatograph equipped with a Rheo-
dyne injector valve with a 20 μL loop. The detection of
analytes was monitored at emmision 365 nm after exci-
tation at 300 nm by L-7485 fluorescense-detector
(Darmstadt, Germany). Chromatograms were recorded
on a Merck Hitachi D-7500 integrator. Mobile phases
were degassed using Merck L 7612 solvent degasser.
The separation of these compounds was achieved on
Waters
®-C18 column (250 mm, 4.6 mm i.d., 5 m parti-
cle size) using isocractic mobile phase containing a mix-
ture of acetonitrile and 0.01 M dihydrogenphosphate
buffer 45:55 (v/v). The analysis was performed at a flow
rate of 1 mLmin
-1. The pH of the buffer was adjusted
with orthophosphoric acid. Prior to any analysis, the
mobile phase was filtered using 0.45 μm filters. The sys-
tem was equilibrated with the mobile phase before
injection.
Reagents and chemicals
-Working reference standard of SUL and MEB were
kindly supplied by RAMEDA (The Tenth of Ramadan)
Co. for Pharmaceutical Industries & Diagnostic
Reagents, 6
th of October City, Egypt.
-Colona
® tablets (Batch No. 09425, labelled to contain
25 mg SUL and 100 mg MEB per tablet) are from
RAMEDA (The Tenth of Ramadan) Co. for Pharmaceu-
tical Industries & Diagnostic Reagents, 6
th of October
City, Egypt.
- Acetonitrile- HPLC grade (Riedel-de Haen, Ger-
many), Phosphoric acid 85% (Riedel-de Haen, Germany).
Analytical grade potassium dihydrogenphosphate and
orthophosphoric acid were obtained from Prolabo
(Paris, France). HPLC grade methanol (MeOH) was
obtained from Prolabo (Paris, France).
- SUL impurities, 2-methoxy-5-sulfamoyl benzoic acid
methyl ester (sules) (CAS No. 33045-52-2) and 2-amino-
methyl-1-ethylpyrrolidine (sulam) (CAS No. 26116-12-1)
were imported from Wuhan Yuancheng Technology
Development Co. Ltd., China.
Preparation of standard solutions
Preparation of stock standard solutions Stock stan-
dard solutions of MEB, SUL and SUL impurities (200
μg/mL each) were prepared by accurately weighed 10.0
mg of each of MEB and SUL and transferred to 50 ml
measuring flasks. The compounds were separately dis-
solved in 50 ml of methanol. The stock solutions were
further diluted with the mobile phase to obtain the
working concentration ranges. The standard solutions
were kept in the refrigerator and were found to be
stable for 10 days.
Preparation and separation of the hydrolytic degra-
dation products of MEB 0.5 gm MEB powder was
transferred into 100 ml stoppered flask. 100 mL 1N
NaOH dissolved in methanol was added and the solu-
tion was heated at 45°C for 12 hrs till complete degrada-
tion of MEB (investigated by the disappearance of MEB
spot upon applying qualitative TLC). The solution was
left to evaporate under reduced pressure to residue, 30
ml distilled water was added and the oily part was
extracted with 60 ml ether in divided portions. The
ether extract was washed with 20 ml distilled water in
two fractions and then the ethereal layer was let to eva-
porate at room temperature where a colorless oily resi-
due appeared of 4-(ethyl [2-(4-methoxyphenyl)-1-
methylethyl] amino) butan-1-ol (mebOH) [6]. The pri-
marily separated aqueous layer was acidified with 5N
HCl just till acidic to litmus, where a heavy white preci-
pitate of veratic acid was produced, which was then fil-
tered and washed with 30 ml distilled water added in
divided portions, The white needles of veratic acid were
dried in the oven at 90°C for 1 hr [6]. IR and Mass
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Figure 1 Structural formulae of the studied drugs.
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separated degradation products of MEB (veratic acid) as
shown in Figure 2.
Stock standard solution of veratic acid (200 μg/mL
each) was prepared by accurately weighed 10.0 mg of
veratic acid and transferred to 50 ml measuring flask.
The compound was dissolved in 50 mL of methanol.
The stock solution was further diluted with the mobile
phase to obtain the working standard solution.
Construction of the calibration curves
Aliquots of MEB and SUL covering the working concen-
tration range 10-100 ng/mL for each of MEB and SUL
were quantitatively transferred into a series of 10 mL
volumetric flasks, after being diluted to 10 mL with the
 
 
 
A)
B)
Figure 2 a: IR spectrum of veratic acid. b: Mass spectrum of veratic acid (Mol. Wt. = 182).
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Page 3 of 12mobile phase (pH = 4). 20 μL aliquots were injected (in
triplicate) and calibration curve was constructed by plot-
ting the peak area ratio between a drug and the other
drug as internal standard against the final concentration
of drugs in ng/mL, alternatively, the corresponding
regression equations were derived.
Procedure for the synthetic mixture
Aliquot volumes of MEB and SUL standard solutions in
the ratio of 4:1 were transferred into a series of 10 mL
volumetric flasks. The flasks completed to the volume
with the mobile phase. The procedure described under
section 2.4 was performed.
Procedure for commercial tablets
10 film coated tablets were bleached with methanol
swab and pulverized well. A weighed quantity of the
powder equivalent to 100 mg MEB and 25 mg of SUL
(in their pharmaceutical ratio of 4:1) was transferred
into a small conical flask and extracted with 3 × 30 mL
of methanol. The extract was filtered into a 100 mL
volumetric flask. The conical flask was washed with few
milliliters of methanol. The washings were passed into
the same volumetric flask and completed to the volume
with the same solvent. Aliquots covering the working
concentration range were transferred into 10 mL volu-
metric flasks. The recommended procedure under “Cali-
bration Curve” was performed. The nominal content of
the tablets were determined either from a previously
plotted calibration graph or using the corresponding
regression equation.
Procedure for spiked human plasma
Suitable aliquots of mixture of MEB metabolite (veratic
acid) and SUL stock solutions containing 10.0-50.0 ng/
mL and 10.0-100.0 ng/mL respectively were transferred
into centrifugation tubes. 1.0 ml of human plasma was
added to each tube. Then, alkalinization was achieved
by addition of 0.1 mL of NaOH (1.0 M) and the tubes
were shaken for 1 min. The samples were mixed well
using a vortex mixer and then extracted with 3 × 3 mL
of ethyl acetate/dichloromethane (5:1 v/v) by centrifuga-
tion for 5 min at 4000 rpm. The organic layer was
transferred into an evaporating dish and evaporated till
dryness. The residue was reconstituted in 3 mL metha-
nol [8]. The procedure described under calibration
curve was followed. The nominal content of the drug
w a sd e t e r m i n e df r o mt h ep r e v iously plotted calibration
graph or using the corresponding regression equation.
Procedure for real human plasma
Three healthy volunteers (women around 35 years old)
were administered Colona
® tablets after 8 hours fasting.
Further, 5 mL blood samples were drawn at different
time intervals at 0.5, 1.0, 1.5,2 . 0 ,2 . 5 ,3 . 0 ,3 . 5 ,4 . 0 ,4 . 5 ,
5.0 and 6.0 hr into tubes containing 0.5 ml of 2% EDTA
solution to prevent blood coagulation. The blood was
processed to plasma by centrifugation at 4000 rpm and
15 min. the supernatant plasma samples transferred into
test tubes and the procedure mentioned above was fol-
lowed for the monitoring of drug concentration in
plasma.
Results and discussion
Chromatography
The proposed method permits the separation of MEB
and SUL from degradation product and impurity. Figure
3 shows a chromatogram indicating good resolution of
MEB (tR = 5.0 min.) and SUL (tR =2 . 4 )i np u r ef o r m
and in tablet extract, whereas Figure 4 show good reso-
lution of MEB, MEB metabolite (veratic acid), SUL and
SUL impurity (sules).
In an attempt to optimize the separation of MEB and
SUL and their impurities and degradation products in
bulk and plasma, the effects of some chromatographic
parameters such as mobile phase composition and pH
of the buffer solution were investigated.
Effect of the mobile phase composition
Type of Organic Modifier
Acetonitrile was replaced by methanol but it did not
give good resolved peaks. Acetonitrile was the organic
modifier of choice giving symmetrical narrow peaks.
Ratio of Organic Modifier
The effect of changing the ratio of organic modifier on
the selectivity and
retention times of the test solutes was investigated
using mobile phases containing concentrations of 40-
75% for acetonitrile. Table 1 shows that 45%
acetonitrile was the best one giving well resolved
peaks and highest number of theoretical plates. Ratios
less than 45% resulted in peaks with very long unaccep-
table retention times, whereas ratios higher than 75%
resulted in precipitation in the mobile phase.
Effect of pH
The effect of changing the pH of the mobile phase on
the selectivity and retention times of the test solutes
was investigated using mobile phases of pH ranging
from 3.0-5. Table 1 illustrated that a pH of 4.0 was the
most appropriate one giving well-resolved peaks and
highest number of theoretical plates. pHs higher than
5.0 produced precipitation in the mobile phase.
Ionic Strength of Buffer
The effect of changing the ionic strength of phosphate
buffer on the selectivity and retention times of the test
solutes was investigated using mobile phases containing
concentration of 0.0075- 0.04 M of phosphate buffer.
Table 1 shows that 0.01 M phosphate buffer was found
to be the most suitable giving best resolution and high-
est number of theoretical plates.
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The effect of flow rate on the formation and separation
of peaks of the studied compounds was studied and a
flow rate of 1 mL/min was optimal for good separation
in a reasonable time (Table 1).
Validation of the Method
Concentration Ranges and Calibration Graphs
Under the above described experimental conditions, a lin-
ear relationships was established by plotting peak area ratio
for MEB to 0.1 μg/mL SUL as internal standard against
MEB concentrations and on the other hand, plot peak area
r a t i of o rS U Lt o0 . 1μg/mL MEB as internal standard
against SUL concentrations,. The concentration range was
found to be 10- 100 ng/mL for each drug. Linear regres-
sion analysis of the data gave the following equations:
P = 0.018 + 0.04C (r = 0.9999) for MEB.
P = 0.024 + 0.001C (r = 0.9999) for SUL.
where: C is the concentration of MEB or SUL in ng/
mL and P is the peak area ratio. The high value of the
correlation coefficient (r-values > 0.999) with small
intercept indicate the good linearity of the calibration
graphs. Statistical analysis of the data gave small values
of the standard deviation of the residuals, and the% rela-
tive error, [9] as shown in table 2.
Limit of Quantitation and Limit of Detection
The limits of quantification (LOQ) was calculated
according to ICH Q2B recommendations [10]. The lim-
its of detection (LOD) was also calculated according to
ICH Q2B recommendations [10]. The results of LOD
and LOQ of MEB and SUL respectively are abridged in
Table 2.
LOQ and LOD were calculated according to the fol-
lowing equations [10]:LOQ = 10 s/S
LOD = 3.3 s/S
Where, s is the standard deviation of the intercept of
regression line and S is the slope of regression line of
the calibration curve. Statistical analysis [9] of the
results, obtained by the proposed and the reference
method [4] using Student’s t-test and variance ratio F-
test, shows no significant difference between the perfor-
mance of the two methods regarding the accuracy and
precision, respectively (Table 3).
 
Figure 3 HPLC typical chromatograms of: (A) Synthetic mixture of [(a) 25 ng/mLSUL, (b) 100 ng/mL MEB]. (B) Chromatogram of Colona
®
tablet extract [(a) 25 ng/mL SUL, (b) 100 ng/mL MEB] under the described chromatographic conditions.
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the two drugs on a reversed phase, Bondapak CN col-
umn and UV detection was done at 243 nm using bucli-
zine hydrochloride as internal standard [4].
Accuracy and Precision
Repeatability The repeatability was evaluated by apply-
ing the proposed method for the determination of three
concentrations of MEB and SUL in pure forms on three
successive times, and the results are abridged in Table
4. The low %Error and low % RSD indicates high accu-
racy and high precision of the proposed method
respectively.
Intermediate precision Intermediate precision was per-
formed through replicate analysis of MEB and SUL in
pure form. The results are shown in Table 4, for a per-
iod of 3 successive days.
Application of the method
Pharmaceutical Applications
Selectivity The proposed method was applied for the
determination of the studied drugs in their co-formulated
tablets. The specificity of the method was investigated by
observing any interference encountered from the common
tablet excepients, such as lactose, gelatin, magnesium stea-
rate and starch. These excepients did not interfere with the
proposed method (Table 5). The average percent recoveries
of different concentrations were based on the average of
three replicate determinations. The results shown in Table
4 are in good agreement with those obtained with the
reference method [4]. Figure 3 shows a chromatogram
indicating good resolved peaks of MEB and SUL.
Degradation product of MEB (veratic acid) and impur-
ity of SUL (sules) of is easily detectable and can be
Figure 4 (A) HPLC typical chromatogram of SUL (100 ng/mL) in presence of its sules impurity (1.0%). (B) HPLC typical chromatogram of
separated SUL (25 ng/mL), veratic acid (10 ng/mL), sules (100 ng/mL) and MEB (100 ng/mL).
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the proposed method can be used for the quality control
of the tablets.
Biological applications
The high sensitivity of the proposed method allowed the
determination of MEB metabolite and SUL in biological
fluids by HPLC method. The method was further
applied to the in-vivo determination of both drugs in
real human plasma. Sulpiride is absorbed from gastro-
intestinal tract. Following oral ingestion of a single oral
dose of 50 mg of SUL, a peak plasma concentration of
0.03-0.60 mg/L (mean 0.18 mg/L) is attained in about 4-
7 hours [8]. This value lies within the working concen-
tration range of the proposed method.
After oral administration of mebeverine HCI (270 mg)
to fasted human volunteers, measurable concentrations
of the drug were not found in plasma. By contrast, the
metabolite veratric acid achieved considerable concen-
trations (mean peak plasma concentration of 13.5 μg/
mL at (40-80 min) [11]. Veratic acid (MEB metabolite)
is also highly fluorescent compound and the second
metabolite is mebeverine alcohol which is non-fluores-
cent at the studied pH 4 [12]. However, after oral
administration of mebeverine HCI (2 mg), only traces of
mebeverine were found in plasma with simultaneous
appearance of veratic acid. Veratric acid was achieved
with considerable concentrations (mean peak plasma
concentration of 0.90 μg/mL at (15 min-4 h). The mean
percentage recoveries, % Error and % RSD are abridged
in Table 6. The results show that mebeverine undergoes
rapid and extensive first-pass metabolism involving
hydrolysis of the ester function, as shown in Figure 5
and that very trace circulating concentrations of the par-
ent drug are found in humans [12].
The typical chromatograms for the separation of the
MEB, veratic acid and SUL in real plasma are illustrated
in Figure 6. The plasma samples obtained from the
volunteers were investigated using the previously
Table 1 Effect of experimental parameters on the number of theoretical plates of the studied compounds
Parameter No. of theoretical plates (N) Resolution (Rs)
MEB SUL MEB SUL
Ratio of organic modifier A/B 40/60 1199 2521 3.20 0.345
45/55 3407 4691 6.00 3.95
50/50 2867 1824 5.75 1.77
55/45 1658 911 3.97 1.20
60/40 1255 1348 3.97 1.46
70/30 1946 834 4.90 6.19
75/25 1487 825 4.20 0.99
pH 3.0 2687 1778 5.04 1.55
3.5 1138 1510 3.50 1.52
4.0 3462 4659 6.16 3.70
4.5 1716 2366 5.10 3.10
5.0 1345 1630 5.33 3.10
Ionic strength of phosphate buffer [M] 0.0075 2935 2315 5.08 2.24
0.01 3451 4632 6.16 3.72
0.02 1614 1251 5.60 2.62
0.03 1982 1150 6.20 2.50
0.04 1394 950 5.30 2.40
Flow rate mL/min 0.50 1297 1783 3.6 1.5
0.75 2356 3252 5.20 2.50
1.00 3442 4621 6.20 3.90
1.20 1864 2534 4.75 3.10
1.50 1534 1963 5.80 3.40
Table 2 Performance data of the proposed method
Parameter Mebeverine Sulpiride
Concentration range (ng/mL) 10-100 10-100
Limit of detection (LOD) (ng/mL) 0.85 0.73
Limit of quantification (LOQ) (ng/mL) 2.57 2.21
Correlation coefficient (r) 0.9999 0.9999
Slope 0.04 0.001
Intercept 0.018 0.024
standard deviation of the residuals (Sy/x) 0.017 0.0005
standard deviation of the intercept (Sa) 0.012 0.0003
standard deviation of the slope(Sb) 2.23 × 10
-5 7.0 × 10
-7
%RSD 0.756 0.626
% Error 0.267 0.221
Sy/x, Standard deviation of the residuals; Sa, Standard deviation of the
intercept; Sb Standard deviation of the slope
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Parameter Concentration taken
(ng/mL)
Concentration found
(ng/mL)
% Found Reference method [4]
1- MEB 10 10.06 100.56 100.46
20 20.29 101.44 99.53
30 30.12 100.40 100.15
40 39.74 99.36
50 49.78 99.55
60 60.01 100.02
80 79.46 99.33
100 100.54 100.54
X’ 100.22 100.04
± S.D. 0.757 0.473
t-test 0.0.379 (1.833)
F-value 2.55 (4.74)
2- SUL 10 10.08 100.78 100.9
20 19.80 99.00 99.0
30 30.10 100.34 100.3
40 40.05 100.13
50 50.00 100.00
60 59.71 99.52
80 80.43 100.53
100 99.82 99.825
X’ 99.96 100.0
± S.D. 0.390 0.92
t-test 0.08 (1.833)
F-value 2.41 (4.74)
Values between parenthesis are the tabulated t and F values, respectively at p = 0.05.
Table 4 Application of the proposed method for determination of the studied drugs in their synthetic mixtures and in
co-formulated tablets
Sample Concentration taken
(ng/mL)
Concentration found (ng/mL) Recovery %
MEB SUL MEB SUL MEB SUL
1-MEB and SUL mixture 40 10 40.23 9.96 100.58 99.59
60 15 59.38 15.12 98.97 100.82
80 20 80.53 19.89 100.66 99.47
100 25 99.86 25.03 99.86 100.11
X’ 100.01 99.99
± S.D. 0.787 0.61
%RSD 0.786 0.61
%Error 0.278 0.300
2-Colona
® tablets
a
(MEB 100 mg +SUL 25 mg/tab.) 40 10 40.18 10.06 100.45 100.65
Batch # 09425. 60 15 60.26 14.97 100.44 99.77
80 20 78.92 19.86 98.65 99.30
100 25 100.63 25.11 100.63 100.42
X’ 100.04 100.03
± S.D. 0.930 0.614
%RSD 0.933 0.614
%Error 0.467 0.307
-Each result is the average of three separate determinations.
-
a Product of Rameda Co. for Pharmaceutical Industries and Diagnostic Reagents 6
th of October City. Egypt.
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the results obtained are shown in Figure 7 showing
maximum plasma levels are reached after 3.5 hours for
SUL and veratic acid. Hence, the proposed method
allows for the therapeutic drug monitoring for MEB and
SUL mixture level in plasma.
Table 5 Validation of the proposed method for determination of MEB and SUL raw materials using the proposed
method
Concentration added (ng/mL) % recovery % RSD % Error
MEB
Intra-day
40 100.85 ± 0.636 0.630 0.364
60 100.37 ± 0.490 0.488 0.281
80 100.2 ± 0.854 0.852 0.491
Inter-day
40 99.75 ± 0.921 0.925 0.534
60 99.08 ± 0.589 0.594 0.343
80 100.53 ± 0.650 0.646 0.373
SUL
Intra-day
10 100.23 ± 0.737 0.735 0.424
15 101.03 ± 1.023 1.012 0.584
20 100.06 ± 0.573 0.572 0.330
Inter-day
10 98.96 ± 0.824 0.832 0.480
15 99.99 ± 0.961 0.961 0.554
20 100.78 ± 0.762 0.756 0.436
N.B. Each result is the average of three separate determinations.
Table 6 Application of the proposed method for determination of the studied drugs in spiked and real human plasma
Sample Concentration taken (ng/mL) Concentration found (ng/mL) Recovery %
Veratic acid SUL Veratic acid SUL Veratic acid SUL
1-Spiked plasma sample
a- Intra-day precision 10 10 10.32 9.62 103.19 96.23
25 50 24.34 51.04 97.36 102.09
50 100 50.28 99.50 100.55 99.50
X’ 100.36 99.27
± S.D. 2.92 2.95
%RSD 2.91 2.95
%Error 1.68 1.69
b- Inter- day precision 50 100 50.56 95.32 101.12 95.30
50 100 51.10 98.57 102.20 98.57
50 100 49.95 101.24 99.90 101.24
X’ 101.07 98.37
± S.D. 1.15 2.97
%RSD 1.13 3.02
%Error 0.65 1.74
2- Real plasma sample 100 100 91.87 92.48 91.87 92.48
100 100 90.12 93.76 90.12 93.76
100 100 86.25 87.98 86.25 87.98
X
- 89.41 91.40
± S.D. 2.87 3.03
%RSD 3.21 3.321
%Error 1.85 1.91
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Figure 5 In vivo hydrolysis of mebeverine into mebeverine alcohol and veratic acid and the subsequent oxidation of mebeverine
alcohol to mebeverine acid.
 
Figure 6 (A) Plasma samples obtained 1.0 hr after oral administration of Colona
® tablet under the chromatographic conditions. (B) Plasma
samples obtained 3.5 hr after oral administration of Colona
® tablet under the chromatographic conditions.
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A new simple and sensitive method was explored for the
simultaneous determination of MEB and SUL in their
combined tablets. The HPLC method using florescence
detection, by virtue of its high sensitivity, could be
applied to the analysis of both drugs in their co-formu-
lated dosage forms and biological fluids; it was possible
to measure concentrations as low as 0.85 and 0.73 ng/
mL for MEB and SUL respectively with good accuracy
Moreover, the proposed method allowed therapeutic
monitoring of MEB metabolite (veratic acid) in real
human plasma without interference with SUL. More-
over, the proposed method is simple, time saving.
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Figure 7 Plasma concentration - time profiles of MEB, veratic acid and SUL after oral administration of Colona
® tablets [2 x(100 mg
MEB + 25 mg SUL)].
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